CHARLES RIVER FREE

The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish themselves as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development. ДЇrom 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China. Proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal. In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. The company was known then as Charles River Laboratories. In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The chairman and chief executive officer is James C. The work done in San Diego-the breeding of rodents that scientists use to test compounds-will be moved to Hollister, which is about 90 miles from San Francisco. In California, the company also has sites in the town of Hollister and in South San Francisco. In April 2019, Charles River announced it will be ceasing its San Diego-area operations, moving the work to one of its sites in Northern California. In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland. The company then introduced preconditioning services in 2005 to provide their customers with study-ready animals. The same year, they were named 'Company of the Year' by The Boston Globe. And testing on Monkeys in Sparks, Nevada.Д¬harles River launched the Humane Care Imperative in 2002, designed to raise awareness and train their employees on the importance of animal welfare.

CHARLES RIVER FREE

They purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme in 1992 and started offering in vitro endotoxin testing two years later.Д«etween 19, the company acquired Endosafe, Inc., was bought back from Bausch & Lomb by Jim Foster, acquired Sierra Biomedical, expanded its portfolio to offer biopharmaceutical services, and went public on the New York Stock Exchange. In the 1990s, Charles River expanded their portfolio further. In 1988, the organization started to expand their portfolio to include the creation of transgenic mice and rats. During this time, Henry and Jim Foster are still in charge of the company. Three years later, they were acquired by Bausch & Lomb. The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981.

The organization became an international entity in 1966 with the opening of a new animal production facility in France. In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. In an effort to fulfil the regional need for laboratory animal models, he bred, fed, and cared for the animals and personally delivered them to local researchers.

The company has over 90 facilities, operates in 20 countries, and employs approximately 18,400 people worldwide.Д¬harles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-man laboratory in Boston, overlooking the Charles River.

Its customers include leading pharmaceutical, biotechnology, agrochemical, government, and academic organization around the globe. The company's broad portfolio allowed them to support the development of approximately 85% of FDA-approved drugs in 2018. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry (for example, contract research organization services) and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing. Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries.

Charles river